GT
ESPR

Glenmede Trust’s Esperion Therapeutics ESPR Stock Holding History

Glenmede Trust’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,071
Closed -$209K – 1212
2020
Q4 		$209K Sell
8,071
-4,120
-34% -$123K ﹤0.01% 1048
2020
Q3 		$453K Buy
12,191
+3,060
+34% +$121K ﹤0.01% 817
2020
Q2 		$468K Sell
9,131
-1,065
-10% -$44.6K ﹤0.01% 779
2020
Q1 		$607K Hold
10,196
– – ﹤0.01% 852
2019
Q4 		$607K Buy
+10,196
New +$458K ﹤0.01% 852
2016
Q3 		– Sell
-500
Closed -$4K – 2606
2016
Q2 		$4K Buy
+500
New +$8.29K ﹤0.01% 2275

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return